Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) stock rose 2.4% following the announcement that an abstract on its CRB-701 clinical study has been accepted for presentation at the ...

Holdings announced that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the ...

Presentation to include the first full pharmacokinetic and pharmacodynamic (PK/PD) data from the BEXMAB study; supports bexmarilimab's advancement into Phase III TURKU, FI / ACCESS Newswire / July 30, ...